C. Hay

发表

Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study

M. Scott, H. Xiang, D. Hart, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

J. Oldenburg, T. Lissitchkov, C. Hay, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

nonsevere hemophilia A ) mutation and risk of inhibitor development in F8 Factor VIII gene (

J. Astermark, R. Keenan, J. Oldenburg, 2014 .

GENERAL INTRODUCTION AND OUTLINE OF THE THESIS

J. Astermark, R. Keenan, J. Oldenburg, 2012 .

THROMBOSIS AND HEMOSTASIS Factor VIII gene ( F 8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

J. Astermark, R. Keenan, J. Oldenburg, 2013 .

The incidence of factor VIII inhibitors in the United Kingdom, 1990‐93

C. Hay, B. Colvin, F. Hill, 1995, British journal of haematology.

HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A

W. Ollier, C. Hay, B. Colvin, 1997, Thrombosis and Haemostasis.

Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A

R. Bagnall, E. Santagostino, K. Fijnvandraat, 1998, Thrombosis and Haemostasis.

The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIa

C. Négrier, C. Hay, 2000, Seminars in thrombosis and hemostasis.

Diagnosis of APC resistance during pregnancy

C. Hay, A. Cumming, R. Campbell Tait, 1996, British journal of haematology.

Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors: a systematic literature review.

M. Makris, R. Liesner, D. Hart, 2019, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

S. Lethagen, M. Laffan, J. Mahlangu, 2015, Journal of thrombosis and haemostasis : JTH.

Is it congenital or acquired von Willebrands disease?

J. Thachil, B. Bigger, C. Hay, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

A. Blann, A. Herrick, M. Jayson, 1996, Annals of the rheumatic diseases.

Inhibition of collagen-induced platelet aggregation as the result of cleavage of alpha 2 beta 1-integrin by the snake venom metalloproteinase jararhagin.

C. Hay, M. Zuzel, A. Kamiguti, 1996, The Biochemical journal.

Inhibition of collagen-induced platelet aggregation as the result of cleavage of alpha 2 beta 1-integrin by the snake venom metalloproteinase jararhagin.

C. Hay, M. Zuzel, A. Kamiguti, 1996, The Biochemical journal.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study

C. Négrier, C. Hay, C. Ludlam, 1997, Thrombosis and Haemostasis.

Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency

J. Burthem, J. Thachil, C. Hay, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)

P. Giangrande, J. Goudemand, C. Négrier, 2011, Journal of thrombosis and haemostasis : JTH.

FDA Approves New Tuberculosis Drug: Bedaquiline (Sirturo®)

C. Hay, Kent Wilin, Andrew M. Roecker, 2013 .

VIM-D salvage chemotherapy in Hodgkin's disease

C. Hay, R. Spearing, J. Nash, 2004, Cancer Chemotherapy and Pharmacology.

Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia

L. Boggio, S. Arkin, M. Mancuso, 2018, Journal of thrombosis and haemostasis : JTH.

Inhibition of lymphocyte IL2‐receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs

C. Hay, M. Duggan-Keen, P. McEvoy, 1990, British journal of haematology.

The C677T MTHFR variant and the risk of venous thrombosis.

C. Hay, A. Cumming, S. Keeney, 1997, British journal of haematology.

Evaluation of the use of global haemostasis assays to monitor treatment in factor XI deficiency

J. Burthem, J. Thachil, C. Hay, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

The principal results of the International Immune Tolerance Study: a randomized dose comparison.

C. Hay, D. DiMichele, 2012, Blood.

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Insights into the mechanism of haemorrhage caused by snake venom metalloproteinases.

C. Hay, R. Theakston, R. Theakston, 1996, Toxicon : official journal of the International Society on Toxinology.

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

S. Darby, P. Giangrande, Christine A. Lee, 2007, Blood.

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

T. Baglin, M. Makris, R. Liesner, 2007, Blood.

Safety Profile of Porcine Factor VIII and Its Use as Hospital and Home-Therapy for Patients with Haemophilia-A and Inhibitors: the Results of An International Survey

P. Mannucci, E. Santagostino, M. Laffan, 1996, Thrombosis and Haemostasis.

Clinical assessment of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A

T. Baglin, M. Makris, K. Kuliczkowski, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-stage Clotting and Chromogenic Factor VIII Assay

P. Giangrande, E. Gomperts, C. Hay, 1999, Thrombosis and Haemostasis.

Difficult clinical challenges in haemophilia: international experiential perspectives

P. Giangrande, E. Santagostino, C. Kessler, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

How I treat inhibitors in haemophilia

M. Makris, R. d'Oiron, C. Hay, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1

A. Shapiro, M. Tarantino, C. Hay, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

R. Liesner, D. Hart, B. Palmer, 2014, Blood.

PROGRESSIVE LIVER DISEASE IN HAEMOPHILIA: AN UNDERSTATED PROBLEM?

C. Hay, F. Preston, J. Underwood, 1985, The Lancet.

Inhibitors in Mild and Moderate Haemophilia A

C. Hay, C. Lee, 2008 .

Factor VIII inhibitors in mild and moderate‐severity haemophilia A

R. Bagnall, E. Santagostino, C. Kessler, 1998, Thrombosis and haemostasis.

Osteopenic fractures in pregnancy: Is low molecular weight heparin (LMWH) implicated?

C. Hay, T. Johnston, C. Shiach, 2008, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

H. Ehrlich, A. Shapiro, P. Collins, 2009 .

The international immune tolerance study: a multicenter prospective randomized trial in progress

C. Hay, D. DiMichele, 2006, Journal of thrombosis and haemostasis : JTH.

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

T. Baglin, P. Collins, C. Hay, 2000 .

Elective Surgery on Factor VIII Inhibitor Patients Using Continuous Infusion of Recombinant Activated Factor VII

P. Collins, C. Hay, G. Savidge, 2001, Thrombosis and Haemostasis.

1 Acquired haemophilia

C. Hay, 1998 .

Granular common acute lymphoblastic leukaemia in adults: A morphological study

C. Hay, D. Barnett, C. Hay, 1987, European journal of haematology.

Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study

L. Valentino, D. Warad, V. Rodriguez, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Prothrombin fragment F1 + 2: correlations with cardiovascular risk factors.

J. Duguid, C. Hay, J. A. Jenkins, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A Whole Blood, Multiplex PCR Detection Method for Factor V Leiden and the Prothrombin G20210A Variant

C. Hay, A. Cumming, S. Keeney, 1999, Thrombosis and Haemostasis.

Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia

G. Dolan, C. Hay, C. Hay, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

66. Hemophilia Databases

C. Hay, 2014 .

Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases

A. Wakefield, C. Hay, M. G. Brook, 1995, Digestive Diseases and Sciences.

Arterial thrombosis in the nephrotic syndrome.

P. Mcclelland, C. Hay, I. Fahal, 1994, Postgraduate medical journal.

Diagnosis and management of acquired coagulation inhibitors : a guideline from UKHCDO A United Kingdom Haemophilia Centre Doctors ’ Organization ( UKHCDO ) guideline approved by the British Committee for Standards in Haematology

R. Liesner, D. Hart, P. Collins, 2013 .

Anticardiolipin antibodies in leptospirosis.

C. Hay, M. Palmer, G. Pinn, 1991, Journal of clinical pathology.

Lack of effect of a 24-hour infusion of iloprost in intermittent claudication.

P. Waller, M. Greaves, L. Ramsay, 1987, Thrombosis research.

Report to the Penrose Enquiry From : Dr

C. Hay, 2012 .

Report to the Penrose Inquiry From : Dr

C. Hay, 2012 .

Report to the Penrose Inquiry

C. Hay, 1995 .

Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.

C. Hay, B. Colvin, F. Hill, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.

E. Santagostino, C. Hay, C. Kasper, 1993, Seminars in hematology.

An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease

P. Collins, C. Hay, D. Keeling, 2006, Thrombosis and Haemostasis.

Prevalence of the prothrombin gene G20210A variant in an UK anticoagulant clinic population

C. Hay, A. Cumming, S. Keeney, 1997 .

The factor VIII treatment history of non‐severe hemophilia A

C. Santoro, K. Fischer, M. Kruip, 2020, Journal of Thrombosis and Haemostasis.

Porcine factor VIII: past, present and future.

C. Hay, 2000, Haematologica.

Properties of Fibrinogen Cleaved by Jararhagin, a Metalloproteinase from the Venom of Bothrops jararaca

J. Slupsky, C. Hay, M. Zuzel, 1994, Thrombosis and Haemostasis.

European retrospective study of real‐life haemophilia treatment

J. Oldenburg, C. Hermans, G. Dolan, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients

R. Tait, F. Leebeek, R. Mathôt, 2020, Thrombosis and Haemostasis.

EUHASS: The European Haemophilia Safety Surveillance system.

P. Mannucci, T. Lambert, M. Makris, 2011, Thrombosis research.

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

R. Liesner, C. Hay, D. Keeling, 2006, British journal of haematology.

Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery

T. Baglin, M. Makris, A. Dmoszyńska, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Hindfoot fusion in haemophilic arthropathy: 6‐year mean follow‐up of 41 procedures performed in 28 adult patients

E. Rodríguez‐Merchán, C. Hay, M. Brkljac, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

The impact of sport on health status, psychological well‐being and physical performance of adults with haemophilia

K. Khair, C. Hay, E. Tuddenham, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.

R. Liesner, B. Palmer, P. Collins, 2011, Blood.

Inhibitors to Factor VIII/IX: Treatment of Inhibitors—Immune Tolerance Induction

C. Hay, 2007 .

The epidemiology of factor VIII inhibitors

C. Hay, C. Hay, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

M. Makris, D. Hart, P. Collins, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

R. Liesner, D. Hart, B. Palmer, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

J. Oldenburg, V. Jiménez‐Yuste, S. Lethagen, 2019, BMJ Open.

Weekly recombinant FIX prophylaxis for severe haemophilia B in normal clinical practice: data from UKHCDO and Finland

M. Scott, H. Xiang, C. Hay, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

C. Kessler, A. Klukowska, N. Zozulya, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

C. Kempton, D. Quon, M. Makris, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in haemophilia: clinical aspects

S. Antunes, C. Hay, G. Rivard, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion of factor VIII for surgery and major bleeding.

C. Hay, G. Savidge, H. Doughty, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation

G. Dolan, M. Scott, H. Xiang, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

P. Mannucci, B. Hayward, M. Recht, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A

T. Baglin, M. Makris, K. Kuliczkowski, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

The Incidence of Factor VIII and Factor IX Inhibitors in the Hemophilia Population of the UK and Their Effect on Subsequent Mortality, 1977–991*

S. Darby, P. Giangrande, P. Collins, 2006 .

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

A. Akinc, D. Bevan, K. Pasi, 2015 .

Purchasing factor concentrates in the 21st century through competitive tendering

C. Hay, C. Hay, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company

A. Iorio, J. Oldenburg, V. Jiménez‐Yuste, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.

H. Ehrlich, A. Shapiro, P. Collins, 2009, Expert opinion on biological therapy.

Inhibitors in nonsevere haemophilia A: outcome and eradication strategies

V. Jiménez‐Yuste, K. Khair, F. Smiers, 2015, Thrombosis and Haemostasis.

Induction of Tolerance Using Porcine Factor VIII

C. Hay, Y. Laurian, 1996, Vox sanguinis.

Innovative use of porcine factor VIII:C for immune tolerance induction.

C. Hay, 1991, The American journal of medicine.

Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy.

C. Hay, Y. Laurian, F. Preston, 1990, Blood.

inhibitors treated with porcine VIIIC by home therapy Induction of immune tolerance in patients with hemophilia A and

C. Hay, Y. Laurian, F. Preston, 2011 .

Porcine Factor VIIIC in the Management of Patients With Factor VIII Inhibitors

C. Hay, P. Bolton-Maggs, 1991 .

First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

M. Makris, R. Liesner, D. Hart, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

The Effect of Chronic Exposure to Clotting Factor Concentrates on the Immune System

C. Hay, 1991 .

The immunogenicity of ReFacto AF (moroctocog alfa AF‐CC) in previously untreated patients with haemophilia A in the United Kingdom

B. Palmer, C. Hay, E. Chalmers, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update

M. Makris, R. Liesner, J. Motwani, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Porcine factor VIII: current status and future developments

C. Hay, C. Hay, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Porcine factor VIII therapy in patients with factor VIII inhibitors.

C. Hay, J. Lozier, 1995, Advances in experimental medicine and biology.

NON-A, NON-B HEPATITIS AND HEAT-TREATED FACTOR VIII CONCENTRATES

M. Greaves, C. Hay, F. Preston, 1985, The Lancet.

Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.

E. Santagostino, N. Ciavarella, C. Hay, 1994, Seminars in hematology.

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies

P. Volkers, R. Ljung, E. Santagostino, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Summary report of the First International Conference on inhibitors in haemophilia A.

L. Mantovani, P. Mannucci, F. Rosendaal, 2017, Blood transfusion = Trasfusione del sangue.

101HEMB01 Is a Phase 1/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)

A. Rajasekhar, S. Pipe, C. Hay, 2017 .

Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience

P. Mannucci, E. Santagostino, C. Hay, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction : prospective clinical trials. Discussion

Hay, C. Hay, Lenk, 2000 .

A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Creagh, A. Akinc, D. Bevan, 2016 .

Why do inhibitors arise in patients with haemophilia A?

C. Hay, C. Hay, 1999, British journal of haematology.

Inhibitor development in mild and moderate hemophilia A seems to be associated with an increased mortality risk

J. Astermark, P. Kamphuisen, J. Bom, 2011 .

A novel deletion mutation is recurrent in von Willebrand disease types 1 and 3.

P. Collins, C. Hay, P. Bolton-Maggs, 2009, Blood.

Coagulopathy and haemorrhage in human victims of Bothrops jararaca envenoming in Brazil.

D. Warrell, C. Hay, R. Theakston, 1991, Toxicon : official journal of the International Society on Toxinology.

Atypical bullous pyoderma gangrenosum associated with myeloid malignancies.

D. Winfield, A. Messenger, C. Hay, 1987, Journal of clinical pathology.

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

A. Blann, A. Herrick, S. Hollis, 1996, Annals of the rheumatic diseases.

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A. Akinc, D. Bevan, K. Pasi, 2016 .

Didanosine treatment of haemophilic patients infected with HIV

C. Hay, J. Wilde, A. McKernan, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Coagulation abnormalities and ivermectin.

C. Hay, J. Whitworth, A. McNicholas, 1992, Annals of tropical medicine and parasitology.

The Role of Venom Haemorrhagin in Spontaneous Bleeding in Bothrops jararaca Envenoming

C. Hay, R. Theakston, F. França, 1992, Thrombosis and Haemostasis.

Therelationship between inhibition ofvitamin K12,3-epoxide reductase andreduction ofclotting factor activity withwarfarin

A. Breckenridge, B. K. Park, C. Hay, 1988 .

The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin.

A. Breckenridge, B. K. Park, C. Hay, 1988, British journal of clinical pharmacology.

Plasma thrombomodulin in renal disease: effects of renal function and proteinuria.

J. Bone, C. Hay, R. Rustom, 1998, Clinical nephrology.

Ineffectiveness of the inhibition of the main haemorrhagic metalloproteinase from Bothrops jararaca venom by its only plasma inhibitor, alpha 2-macroglobulin.

C. Hay, R. Theakston, M. Zuzel, 1994, Biochimica et biophysica acta.

Predictive markers of chronic liver disease in hemophilia.

M. Greaves, C. Hay, F. Preston, 1987, Blood.

The importance of tissue factor source in the management of Factor VII deficiency

C. Hay, M. Mitchell, J. McVey, 2006, Thrombosis and Haemostasis.

A post‐marketing safety and efficacy assessment of a monoclonal antibody purified high‐purity factor VIII concentrate

C. Hay, C. Lee, G. Savidge, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

EFFECT OF FISH OIL ON PLATELET KINETICS IN PATIENTS WITH ISCHAEMIC HEART DISEASE

C. Hay, C. R. M. Hay, A. P. Durber, 1982, The Lancet.

CYTOMEGALOVIRUS, SERUM β2 MICROGLOBULIN, AND PROGRESSION TO AIDS IN HIV-SEROPOSITIVE HAEMOPHILIACS

C. Hay, P. Bolton-Maggs, K. Mutton, 1989, The Lancet.

Switching factor products: selecting patients and managing the process

K. Heygate, C. Hay, V. Vidler, 2013 .

POLICY AND PRACTICE

K. Heygate, C. Hay, V. Vidler, 2018 .

Porcine factor VIIIC in the management of patients with factor VIII inhibitors.

C. Hay, P. Bolton-Maggs, 1991, Transfusion medicine reviews.

National Hemophilia Databases

C. Hay, 2010 .

First-in-Human Phase 1/2 Clinical Trial of SIG-001, an Innovative Shielded Cell Therapy Platform, for Hemophilia Α

B. Konkle, A. Shapiro, W. Miesbach, 2020 .

Von Willebrand factor, thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systematic sclerosis.

A. Blann, A. Herrick, M. Jayson, 1996 .

Current and future approaches to inhibitor management and aversion.

M. Carcao, M. Recht, B. Reipert, 2006, Seminars in thrombosis and hemostasis.

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

J. Astermark, R. Keenan, V. Jiménez‐Yuste, 2013, Blood.